A Huma-powered Bayer program has broken a #GuinnessWorldRecord! 🚀 In support of Aspirin, and in combination with other initiatives, our technology has powered the highest number of cardiovascular disease (CVD) screenings ever done in 12 hours as part of #WorldHeartDay. We are immensely proud to support the Bayer team in their mission to save millions of lives by breaking down barriers and enhancing accessibility, awareness, and diagnosis of CVD. Guinness World Records #CardiovascularDisease #DigitalHealth
Huma
Software Development
Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research
About us
Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Huma’s technology has powered over 3,000 hospitals and clinics, with 500+ unique deployments across 70+ countries. The software has been used to engage and screen over 35 million individuals, with 1.8 million active users across its various products. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as working with most large pharma companies and CROs. The Huma Cloud Platform offers a technology infrastructure built on strong regulatory foundations to launch digital solutions for healthcare and research. Huma has achieved FDA 510(k) Class II, EU/MDR Class IIb, and Saudi FDA Class C regulatory clearance for its disease-agnostic flagship product, enabling rapid, code-free configuration with the ability to host AI/ML models.
- Website
-
http://www.huma.com
External link for Huma
- Industry
- Software Development
- Company size
- 501-1,000 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2011
- Specialties
- Digital clinical trials, Remote patient monitoring, and Digital companion apps
Locations
-
Primary
Millbank Tower, 21-24 Millbank
London, SW1P 4QP, GB
-
14 Penn Plaza
New York, NY 10001, US
Employees at Huma
-
Ignazio Castiglioni
Co-founder & CEO of HAT, the leading private equity firm investing in technology companies
-
Simon MacKinnon
Technology, Healthcare
-
Dr Rich Khatib
Life and business strategist, entrepreneur, philanthropist. Cofounder & board member of AI unicorn Huma
-
Kaushik Gune
President EVP @ Huma US | ex-McKinsey | INSEAD alum
Updates
-
Mark your calendars for September 25! Join us for an exclusive webinar where industry experts from Alcedis - a HUMA company, AstraZeneca, and CompuGroup Medical SE & Co. KGaA will share groundbreaking insights from the innovative InspeCKD study. The InspeCKD study analyzed over 400,000 anonymized patient records from 1,250 general practices across Germany to uncover important trends in chronic kidney disease (CKD) screening and diagnostics. Learn about the cutting-edge methods used, how real-world data was leveraged, and the strategies developed to overcome the challenges of data integration. Don’t miss this opportunity to gain valuable insights from leaders in the field and stay ahead of the curve. Our speakers: Dr. Nils Kost - Director Evidence at AstraZeneca Philipp Thiele - General Manager of CompuGroup Medical SE & Co. KGaA Frederik M. Mader - Specialist in general medicine and Professor at IU International University Dr. Hendrik Melior - Project Manager Clinical Operations at Alcedis Register here: https://lnkd.in/eCjnSb4y Read more about InspeCKD: https://lnkd.in/eH_5haQV
-
At Huma, we believe that AI is key to enabling personalised care at scale. Our HumaMG program uses advanced machine learning and imaging capabilities to support improved monitoring of disease progression for people with #MyastheniaGravis. On September 26, Huma's Chief Medical Officer Dr Mert Aral and Benjamin Irving, VP ML & Imaging, will be leading a webinar session hosted by the Myasthenia Gravis Foundation of America, Inc., in which they'll share more on the HumaMG app and how it uses AI to enhance the #MG care pathway. Living Better with MG: How AI Enhances Treatment and Management 📅 Date: Thursday, September 26, 12pm EST 🔗 Register here:https://lnkd.in/efa96_nJ 🔗 Learn more about HumaMG: https://lnkd.in/eekJTUxQ
-
Meet Huma at #ESMO2024! Dr Mert Aral, our Chief Medical Officer and Hanno Härtlein, Head of Clinical Trials at Alcedis - a HUMA company will be joining at the ESMO - European Society for Medical Oncology conference in Barcelona next week. Get in touch!
-
Huma is proud announce the launch of our new app in partnership with Servier Pharmaceuticals, designed to support patients diagnosed with glioma—a type of tumor affecting the brain or spinal cord. Gliomas are the most common type of primary CNS tumor, and they bring with them a range of challenges, from physical symptoms to emotional stress. Our goal is to provide patients and caregivers resources that can support them in navigating this difficult journey. Huma founder & CEO Dan Vahdat said, “Supporting people living with cancer has been a priority at Huma since day one. We are proud to be working with Servier to help glioma patients get access to critical information about their condition and monitor their disease.“ Wendy Poage, Vice President of Servier’s Patient Office, said “At Servier, our unique governance allows us to focus on patient centricity across all aspects of our organization... This app is one example of the ‘beyond the pill’ digital solutions we are working to provide to patients, caregivers, advocacy groups and others.” The app is now available for free to all patients in the United States, with plans to expand globally in the future. We believe in the power of digital technology to improve cancer care, and this app is just one of the ways we're making a difference. Read more: https://lnkd.in/erauTAHQ
-
This year's #ESCCongress is focused on the theme of "Personalizing Cardiovascular Care." At Huma, providing personalised, predictive care for patients with cardiovascular disease has long been a focus of ours. Huma's Heart Health Risk Assessment tool, launched jointly with Bayer in the US and Saudi Arabia, enables users to get an estimate of their 10-year risk for heart disease in under 3 minutes, without the need for clinic appointments or blood tests. This simple, low-cost, scalable pre-screening tool helps make primary prevention programs for cardiovascular disease even more targeted and cost-effective. Huma developed the algorithm by leveraging 15+ years of longitudinal data from over 500,000 individuals from the UK Biobank dataset. A recent validation of this algorithm in the US by researchers at Huma and The Johns Hopkins University is being presented at #ESCCongress2024. Learn more: https://lnkd.in/ePgkWCrJ
-
Huma is proud to share that our flagship software as a medical device (SaMD) has received CDSCO Class C regulatory certification in India. This achievement is more than just a milestone; it’s a testament to our commitment to enabling access to high-quality, safe, and effective digital health solutions around the world. Huma's founder & CEO Dan Vahdat, said: “Our mission has always been to bring the best care to everyone, from the richest families to the poorest. Digital solutions can make healthcare accessible, consistent, and proactive, and I’m thrilled that with this approval, we can begin impacting 1.5 billion people in India." Read more: https://lnkd.in/djaBzkJx
-
1 month ago, we announced our Series D funding round and the launch of the Huma Cloud Platform. 48 hours later, nearly 80 people from life sciences, healthcare, startups, and universities had all signed on to the waiting list for Huma Cloud Beta. 3 weeks after that, the number was over 200. Today, we launched the Huma Cloud Workspace with the first set of selected customers to begin beta testing. Soon, we hope to make our platform technology open to all. Learn more about how we plan to accelerate the adoption of digital and AI in healthcare, and watch this space: https://workspace.huma.com
-
Join us at #ESCCongress where researchers from Johns Hopkins Medicine, Huma and Bayer will be presenting a poster on the US validation of Huma's risk score for assessing risk of future cardiovascular events. Learn more about our heart health risk score tool, which has been launched in the US and Saudi Arabia: https://lnkd.in/ePgkWCrJ
Bayer Expands Partnership with Huma: Digital Heart Risk Assessment Tool Expands to Saudi Arabia
huma.com
-
Huma was named to Crunchbase's Unicorn Board, following a recent Series D funding round of $80M. 🦄🦄🦄 🔗 Learn more about why Huma made the cut: https://lnkd.in/eD5WXwjt 🎉 Congratulations to the companies that joined us on the list, including Flo Health Inc., Element Biosciences, Skild AI, Harvey, Chainguard, and Infinite Reality among others 🎉
Lucky 13: A Baker’s Dozen Join Unicorn List In July
news.crunchbase.com